Minerva Neurosciences, Inc. — FY 2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018; the filing also reports quarterly results, including the fourth quarter. Minerva is a clinical-stage CNS biopharmaceutical company with four candidates: roluperidone, seltorexant, MIN-117 and MIN-301. It had no approved products and generated no product revenue.
Financial performance and position
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $34.9 million | $30.3 million |
| General and administrative expense | $16.8 million | $10.9 million |
| Net loss | $50.2 million | $31.5 million |
| Net loss per share, basic and diluted | $1.29 | $0.83 |
| Net cash used in operating activities | $41.9 million | Net cash provided of $3.1 million |
- Operating expenses increased 26% to $51.7 million. R&D growth reflected roluperidone Phase 3 and MIN-117 Phase 2b activity; G&A rose mainly due to higher stock compensation and staffing for pre-commercial work.
- 2017 net loss benefited from a $9.4 million income-tax benefit related to tax-law changes; there was no tax benefit in 2018. Investment income increased to $1.7 million from $0.9 million, while interest expense declined to $0.1 million from $0.6 million.
- Fourth-quarter 2018 operating loss was $13.6 million and net loss was $13.2 million, or $0.34 per share. Fourth-quarter 2017 reported an operating loss of $9.5 million and net income of $0.2 million, reflecting the unusual tax benefit.
- At year-end, cash, cash equivalents, restricted cash and marketable securities totaled $88.1 million, versus $133.3 million at December 31, 2017. Current assets were $90.0 million and current liabilities $3.6 million. Accumulated deficit was $214.6 million.
- Operating cash use was partly offset by $69.5 million of net cash from investing activities, principally maturities of marketable securities. Financing used $3.3 million, including debt repayments.
- The $10 million term loan matured and was repaid in August 2018; no borrowings remained at year-end. Deferred revenue was $41.2 million, principally relating to the Janssen collaboration. No product-sales margin is applicable because there was no product revenue.
Programs, outlook and material developments
- Roluperidone: The pivotal Phase 3 trial for schizophrenia negative symptoms was underway, targeting approximately 500 patients. Management expected enrollment completion in the first half of 2019 and 12-week top-line results in mid-2019. A healthy-volunteer dose-escalation study reported no serious adverse events; the filing also discusses cardiac-safety observations and prior QT/QTc concerns.
- MIN-117: A U.S./Europe Phase 2b MDD trial began in April 2018, with approximately 324 patients planned. Top-line results were expected in the first half of 2019. A U.S. patent application for potential pain treatment was also described; this was preclinical evidence, not clinical efficacy.
- Seltorexant: Phase 2b studies in MDD and insomnia were ongoing. Management expected results during the second quarter to mid-2019. Enrollment in one MDD study had been temporarily suspended over a packaging issue and restarted in the second quarter of 2018. Under the Janssen amendment, Minerva received $30 million upfront in 2017 and had potential further payments of $40 million tied to a Phase 3 insomnia trial. The upfront payment and forgiven accrued collaboration costs remain deferred and are recognized as related services are performed. After Decision Point 4, expected in the second half of 2019, either party could opt out; continuing could require Minerva to fund insomnia trials and 40% of Phase 3 MDD costs.
- MIN-301: Still in preclinical development; the company was preparing for an investigational filing and anticipated a Phase 1 study afterward. The regulatory pathway had not been confirmed.
Management stated that year-end liquid resources should cover cash commitments for at least 12 months after issuance of the financial statements, while also noting that additional capital would be needed to fund operations and later-stage development. Future financing was not assured. The company expected continued losses and negative operating cash flow; clinical outcomes, trial timing, regulatory review, manufacturing and commercialization remain uncertain. It relied on third parties for clinical trials and manufacturing and had only 13 full-time employees. The filing reported no material litigation, no off-balance-sheet arrangements and no subsequent events. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal controls because of the company’s emerging-growth-company status.
Important facts for investors to verify
- Subsequent roluperidone Phase 3 results, enrollment progress and any regulatory feedback on the proposed indication and endpoints.
- Results and safety findings from the MIN-117 and seltorexant Phase 2b programs, including whether the filing’s stated 2019 timelines were met.
- Current cash runway and financing needs relative to trial costs; whether additional capital or partnerships were secured and on what terms.
- Janssen collaboration economics and decision rights after Decision Point 4, including potential payments, opt-out choices and future cost-sharing obligations.
- Deferred-revenue recognition, patent coverage and remaining protection periods, and any impairment indicators affecting the $34.2 million in-process R&D asset and $14.9 million goodwill balance.